Progestins in HRT: Sufferance or desire?

Maturitas

Volumn 62, Issue 4, 2009, Pages 371-375

  Skouby, Sven O ^a,b   Jespersen, Joergen ^b  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^b UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

Author keywords

Cardiovascular disease; Hormone therapy; Menopause; Metabolism; Progestins

Indexed keywords

CHLORMADINONE ACETATE; CYPROTERONE ACETATE; DESOGESTREL; DROSPIRENONE; ESTRADIOL; GESTAGEN; GLUCOSE; HIGH DENSITY LIPOPROTEIN; HYDROXYPROGESTERONE; INSULIN; LEVONORGESTREL; LOW DENSITY LIPOPROTEIN; MEDROXYPROGESTERONE ACETATE; MEGESTROL ACETATE; NOMEGESTROL; NORETHISTERONE; NORGESTIMATE; PREGNANEDIOL; SEX HORMONE;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR EFFECT; CARDIOVASCULAR RISK; DRUG BIOAVAILABILITY; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG PROTEIN BINDING; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HEMOSTASIS; HORMONE SUBSTITUTION; HUMAN; INFLAMMATION; INSULIN BLOOD LEVEL; POSTMENOPAUSE; REVIEW;

CARDIOVASCULAR SYSTEM; DRUG ADMINISTRATION ROUTES; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; POSTMENOPAUSE; PROGESTERONE; PROGESTINS;

EID: 67349269577     PISSN: 03785122     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.maturitas.2008.12.019     Document Type: Review

References (23)

1. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002; 288:321-333.
2. Rossouw J.E., Prentice R.L., Manson J.E., et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA 297 (2007) 1465-1477
3. Million Women Study collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 362 (2003) 419-427
4. Vickers M.R., MacLennan A.H., Lawton B., et al. Main morbidities recorded in the Women's International Study of Long Duration Oestrogen after Menopause (WISDOM): a randomised controlled trial of hormone replacement therapy in postmenopausal women. BMJ 235 (2007) 339-351
5. Rosano G.M., Webb C.M., Chierchia S., et al. Natural progesterone, but not medroxyprogesterone acetate, enhances the beneficial effect of estrogen on exercise-induced myocardial ischemia in postmenopausal women. J Am Coll Cardiol 36 (2000) 2154-2159
6. Sitruk-Ware R., Husmann F., Thijssen J.H., et al. Role of progestins with partial antiandrogenic effects. Climacteric 3 (2004) 238-254
7. Smiths C.L., and ÓMalley B.W. Coregulator function: a key to understanding tissue specificity of selective receptor modulators. Endocr Rev 25 (2004) 45-71
8. Kuhl H. Pharmacology of progestins. Basic aspects - progesterone derivatives. Menopause Rev VI (2001) 9-16
9. Skouby S.O., Gram J., Andersen L.F., et al. Hormone replacement therapy: estrogen and progestin effects on plasma C-reactive protein concentrations. Am J Obstet Gynecol 186 (2002) 969-977
10. Andersen L.F., Gram J., Skouby S.O., et al. Effects of hormone replacement therapy on hemostatic cardiovascular risk factors. Am J Obstet Gynecol 180 (1999) 283-289
11. Salpeter S.R., Walsh J.M., Greyber E., Ormiston T.M., and Salpeter E.E. Mortality associated with hormone replacement therapy in younger and older women: a meta-analysis. J Gen Intern Med 19 (2004) 791-804
12. White W.B., Pitt B., Preston R.A., and Hanes V. Antihypertensive effects of drospirenone with 17-beta-estradiol, a novel hormone treatment in postmenopausal women with stage 1 hypertension. Circulation 112 (2005) 1979-1984
13. Sidelmann J.J., Jespersen J., Andersen L.F., et al. Hormonal Replacement Therapy and hypercoagulatibilty: results from the Prospective Danish Climacteric Study. BJOG 110 (2003) 541-547
14. Bongard V., Ferrières J., Ruidavets J.B., et al. Transdermal estrogen replacement therapy and plasma lipids in 693 French women. Maturitas 30 (1998) 265-272
15. Lakka H.M., Laaksonen D.E., Lakka T.A., et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 21 (2002) 2709-2716
16. Walton C., Godsland I., Proudler A., et al. The effects of the menopause on insulin sensitivity, secretion and elimination in nonobsese, healthy women. Eur J Clin Invest 24 (1993) 466-473
17. Manassiev N.A., Godsland I.F., Crook D., et al. Effect of postmenopausal oestradiol and dydrogesterone therapy on lipoproteins and insulin sensitivity, secretion and elimination in hysterectomised women. Maturitas 42 (2002) 233-242
18. Sargeant L.A., Wareham N.J., and Khaw K.T. Hormone replacement therapy and glucose tolerance in EPIC-Norfolk: a population-based study. Diab Metab Res Rev 16 (2000) 20-25
19. Kanaya A.M., Herrington D., Vittinghoff E., et al. Glycemic effects of postmenopausal hormone therapy: the heart and estrogen/progestin replacement study: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 138 (2003) 1-9
20. Margolis K.L., Bonds D.E., Rodabough R.I., et al. Effect of oestrogen plus progestin on the incidence of diabetes in postmenopausal women: results from the women's health initiative hormone trial. Diabetologia 47 (2004) 1175-1187
21. Hernsmeyer R.K., Thompson T.L., Pohost G.M., et al. Cardiovascular effects of medroxyporgesterone acetate and progesterone: a case of mistaken identity. Nat Clin Pract Cardiovasc Med 7 (2008) 387-395
22. Canonico M., Oger E., Plu-Bureau G., et al. Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study. Circulation 7 (2007) 840-845
23. Ahotupa M., Rauramo I., Vasankari T.J., et al. Estrogen replacement therapy in combination with continuous intrauterine progestin administration reduces the amount of circulating oxidized LDL in postmenopausal women: dependence on the dose of progestin. Ann Med 36 (2004) 278-284